Introduction
Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by the absence of spontaneous pubertal development in the face of low sex steroids and gonadotropin levels with otherwise normal pituitary function. When associated with anosmia this HH is termed Kallmanns Syndrome (KS) whereas isolated HH with a normal sense of smell is termed normosmic IHH (nIHH). The incidence varies from 1:10,000 -140,000 with male:female ratio 4:1 with males presenting every 1:8000 [1] . In most patients with IHH, physiological GnRH response restores normal levels of pituitary and Gonadal hormones, allowing for testicular growth and spermatogenesis in men and ovulation in women [2] .
Studies on critical roles of mutated genes causing human GnRH deficiency in the fate specification, proliferation, developmental migration, secretory function and/or survival of GnRH neurons have formed the bases of much of our current understanding of GnRH biology [3] .
Human studies in KS fetuses with olfactory bulb agenesis revealed that premature interruption of the olfactory, vomeronasal (VN), and terminal nerve fibers in the fronto nasal region disrupts the migration of GnRH-1 cells which normally migrate from the nose to the brain along these nerve fibers [4] [5] .
Aetiopathogenesis of Ks
Developmental abnormalities in this migratory journey like those demonstrated with the deletion of the KAL1 gene results in KS [6] [7] . Besides that the fibro blast growth factor (FGF) signaling pathway genes (FGF8 and FGFR1) [8] - [10] , Prokineticin 2 (PROK2) signaling pathway genes [11] - [16] and chromodomain helicase DNA-binding protein7 genes (CHD7) [17] - [19] , and WDR11 [20] , SEMA3A [21] [22] genetic pathways have been identified to haveidentical neurodevelopmental function and implicated in aetiopathogenesis of KS.
WDR11 is an intracellular protein that interacts with the transcription factor EMX1 and semaphorin 3A a secreted protein involved in axonal path finding acting through neuropilin (NRP)1 receptors [21] . Subsequently Cariboni et al. in mice studies suggested SEMA 3A signals reduntantly through both the classical NRP1 and unconventional NRP2 while the usual NRP2 ligand SEMA 3F is dispensable for this process and suggesting mice lacking it recapitulate the anatomical features of the single KS case analyzed [23] . Further Kansakoski et al. 2014 have further included SEMA 7A besides SEMA3A while screening 50 Finnish children (34KS, 16nIHH). They found 3 heterozygous gene variants c458A > G (p.Asn153Ser), c.1253A > G (p.Asn418Ser) and c.1303G > A (p.Val435Ile) in SEMA 3A in 3 KS patients who also had a mutation in FGFR1. Two rare hetrogenous variants c.442 C > T (p.Arg148 Trp) and c.1421G > A (p.Arg474Gln) in SEMA 7A were found in one maleKS patient with a previously identified KISS 1R nonsense variant and one male patient with previously identified KAL1 mutation respectively. They thus concluded that SEMA 3A/SEMA 7A heterozygous missense variants may modify the phenotype of IHH but most probably are not sufficient to cause the disorder alone [24] .
The identification of zinc finger homeodomain factor tea shirt finger family member 1 (TSHZ1), a key regulator of mammalian olfactory bulb (OB) development not only in mice but also in humans as revealed by Ragancokoya et al. has given some answers to a lot of unanswered questions regarding role of PROK2 ligands acting through their Gprotein coupled receptors PROKR2 regarding how their mutations cause both KS and IHH [25] - [28] . They investigated families with congenital aural atresia, heterozygous for loss of function mutations in TSHZ1, and found by microarray analysis, ISH, as well as CHIP that TSHZ1 bound to and regulated the expression of the gene encoding PROKR2, a GPCR essential for OB development and thus giving a clue to the link between PROK2 and KS despite GnRH neurons lacking PROK2 receptors [29] . The OB is one of the few areas in the mammalian brain that produce neurons throughout life.
New interneurons originating from progenitors in the subventicularzone (SVZ) are continually added to the OB. While mRNA of both PROKR1/PROKR2 are expressed in the SVZ and OB, only PROK2 mRNA found here, which functions as a chemo attractant for these neuronal progenitors which follow a rostral migratory stream [28] .
Some of the Prokineticin receptor 2 mutations are not routed to the cell surface, instead they are trapped in the cell secretory pathway. The cell permeant agonist/antagonists have been used to rescue some membrane receptors that are not targeted onto the cell membrane. Chen et al. chose three disease associated mutations W178S, G34D, P290S, which all resulted in retention of PROKR intracellularly. They showed that a small molecule, PROKR2antagonist A457 dramatically increased cell surface expression and rescued the function of P290S PROKR's but had no effect on W178S and G234DPROKR2, Interestingly one of PROKR2 mutations P290S is identified in more than 5% of Maghrebian KS patients who show PROKR mutations in 23.3% of their KS population as opposed to 5% in KS patients from general populations, which have a monogenicrecessive or digenic/oligogenic transmission [30] . Treatment with "chemical chaperones" like 10% glycerol significantly increased the cell surface expression and signaling of P290S and W178S PROKR2. They concluded that some KS-associated intracellularly retained mutant PROKR2 receptors can be functionally rescued suggesting a potential treatment strategy for the patients of KS bearing such mutations [31] . 2008 [19] whereas genes identified in nIHH subjects have been shown to primarily affect neu- and found anosmia/hyposmia is significantly related to anatomical anomalies of the olfactory bulb/tracts, but the prevalence of other developmental anomalies, especially midline defects and neurosensorial hearing loss was high both in HH and KS independent of anosmia/hyposmia. Hence they postulated that from clinical standpoint KS and normosmic HH should be considered as the same complex, developmental disease.
Since there are a lot of lacunae in this study, namely small numbers, not using UPSIT for smell detection and study being partially prospective, partially retrospective it is difficult to draw meaningful conclusions [45] .
Paradox in ICA (Role of OB in GnRH Development)
However this has been further complicated by Moya-Plana reporting isolated congenital anosmia (ICA) and olfactory bulb agenesis without gonadotropin deficiency with threePROKR2 mutations previously described for KS along with one new PROK2 mutation, and incomplete penetrance on investigation of families, on screening for KAL1/FGF8/FGFR1/PROK2/PROKR2 mutations in 25 cases of ICA which suggests the considerable complexity of GnRH neuron development in humans [46] .
While studying 13 most common IHH/KS genes in 48 patients the overall prevalence of digenic gene mutations was found to be 12.5% by Qyaynor et al. In addition 30% of patients without a known mutation had mutation in a single gene. Similarly Sykiotis et al. as well found digenic disease in 11% of 89 patients who had known mutation in one gene and 10 (2.5%) of 397 among allpatients which is the largest series published [43] .
These findings suggest with current knowledge that most IHH/KS patients have monogenic etiology [47] . [48] . Besides that ears, eyes, kidneys and limbs are also influenced by FGF8
Role of FGF in GnRH Development
[49]- [52] , all of which can be affected in CHH [53] . Among the >15 genes implicated in CHH, mutations in FGF8-FGFR1 account for 12% of cases and importantly KAL1 and HS6ST1 (Heparan sulfate-6-O-sulfotransferase 1) [MIM 604846], two genes known to be mutated in CHH, also encode important components of FGF8-FGFR1 signaling.
KAL1 encodes anosmin 1, which enhances FGFR1 signaling by direct physical interactions with the FGFR-FGF-heparansulfate proteoglycan (HSPG) complex on the cell surface. HS6ST1, which encodes a heparansulfotransferase enzyme was found mutated in CHH and that heparan6-O-sulfation was required for anosmin function in vivo [54] . to induce ectodermal progenitors of the OP to acquire neural fate and ii) altered neurogenesis and lack of GnRH neuron specification after chronically reduced fgf8 expression reflected dysgenesis of the nasal region and loss of a specific neurogenic permissive milieu that was defined by mesenchymal signals [64] .
Recently it was demonstrated that CHD7 is essential for the migration of multipotent migratory NC cells, which migrate from the neural tube to many regions in the embryo, where they differentiate into various tissues including craniofacial and heart structures. Figure 1 ).
Diagnosis and Differential Diagnosis
In paediatric endocrinology this differential diagnosis is far more difficult as CHH is rare whereas CDGP is infrequent [79] . Serum inhibin B levels in CHH males correlate with testicular volume and thus with clinical severity of gonadotropin deficiency in the olfactory sulcus [85] . KS, combined pituitary hormone deficiency (CPHD), and septo-optic dysplasia (SOD) all result from developmental defects of the anterior midline in the human forebrain. It has been recently shown that deficient migration of GnRH neurons is also a feature in forebrain formation defects [5] . Hence Raivio et al. studied 103 patients with either CPHD (n = 35), or SOD (n = 68) and investigated them for mutations in genes implicated in the etiology of KS (FGFR1, FGF8, PROKR2, PROK2 and KAL1). Muta- Figure 1 . Courtesy ref [78] -In a subset of adolescents with IHH (and Kallmanns syndrome), mutations in genes that encode critical components of the HPG axis lead to either a lack of GnRH secretion, or action. The etiologies in the remaining cases are undetermined. The lack of GnRH action leads to a deficiency of both priming and hormonal secretion of the gonadotropins in the pituitary and of the leydig/theca cells of the gonads. These characteristics of the H-P-G axis form the physiological basis for the diagnostic tests (indicated in bold face) and typical characteristics (indicated in italic anosmia/hyposmia, small testes, micropenis, cryptorchidism) used to identify patients with a higher likelihood of IHH than CDGP.
tions in FGFR1/FGF8/PROKR2 contributed to 7.8% of their patients with CPHD/SOD which suggests a significant genetic overlap between conditions affecting the development of anterior midline in the human forebrain. Of the SOD 3 patients had heterozygous mutations in FGFR1,with these either shown to alter receptor signaling (p.S450F, p.P483S) or predicted to affect splicing (c.336C > T, p.T112T). One patient was found to have synonymous mutations in FGF8 (c.216G > A, p.T72T), that was shown to affect splicing and ligand signaling activity. Four patients with CPHD/SOD were found to harbor heterozygous rare loss of function variants in PROKR2 (p.R85G, Figure 2 . With permission from Dr Young courtesy ref [84] -Molecular studies performed in male patients of CHH categorized on the basis of smell 1) MRI, 2) Bimanual synkinesis, tooth agenesis, hearing impairment, renal agenesis, cleft lip/palate, high arched palate, pes cavus, ptosis, absent nasal cartilage, hand/foot skeletal abnormalities and iris coloboma 3) Step by step strategy based on familial history and putative mode of disease inheritance (pedigree), and the presence of additional clinical anomalies as mentioned above that may direct the geneticist towards a particular Kallmann gene 4 and 5) For instance 4) KAL 1 is analyzed especially in Kallmann men with mirror movements (bimanual synkinesis) and/or for kidney agenesis and/or when the pedigree suggests an X linked mode of inheritance, whereas 5) in subjects displaying cleft lip/palate FGFR1 mutations are searched in firstline whatever the apparent mode of inheritance 6) in subjects with monoallelic, PROK2 or PROKR2 mutations, search for mutations in other CHH genes to demonstrate a digenic or oligogenic mode of inheritance 7) Analysis of other large genes mentioned below performed in second line, given their lower or unknown prevalence among normosmic CHH and Kallmann men.Sizes of the genes currently sequenced in CHH patients: GNRH1; three exons, GNRHR; three exons,KISS1R;five exons, TAC3; six exons;TACR3;five exons; KAL1; fourteen exons, FGF8, six exons; FGFR1, 18exons; PROKR2, two exons; PROK2, four exons; CHD7; 38exons; WDR11; 29 exons; NSMF (NMDA receptor synaptonuclear signaling and neuronal migration factor-formerly known as NELF); 16 exons. p.R85H, p.R268C) [87] . To further study the role of PROKR2/PROK2, McCabe et al.
further studied 422 patients of congenital hypopituitarism (CH) and detected that variations in PROKR2 but not PROK2 are associated with CH and SOD. They detected 5PROKR2 variants in 11 patients with SOD/CH: novel p.G371R and previously reported p.A51T, p.R85L, p.L173R and p.R268C-the latter three being known as functionally deleterious variants [88] . 
Management
Castaneyra-Perdomo et al. 2014 suggested that although normally treatment is started in KS patients just before puberty early treatment isadvisable, as brain sexualmaturation occurs long before puberty normally at perinatal age. As brain cells implicated in the development of the olfactory and reproductive system have a rostraland a caudalorigin, and the rostral origin is affected by aplasia in KS and the caudal origin does not seem to be affected, the aim of early treatment of KS is to attain brain sexualmaturation at the most appropriate age possible, which may prevent the eunuchoidal behavior and appearance observed in KS [93] .
Role of Testosterone Therapy
The initial goal of treatment for adolescents and young men who present with CHH is to induce physical and behavioral development matching that of normal healthy subjects of same age. This includes development of secondary sex characters like pubic and axillary hair, increase in penis size, voice masculinization and development of muscle mass. Further one aims at correcting the delay in bone maturation and deficient bone mineralization, enhance libido and modify sex behavior. Mostly effective testosterone replacement therapy can lead to a spectacular improvement in quality of life, which demonstrates a causal relationship between testosterone deficiency and these patients symptoms.
Although it is more physiological to achieve such benefits with pulsatile GnRH ad- 
Role of Gonadotropin Therapy

Role of Pulsatile GnRH Therapy
GnRH treatment is successful in inducing virilization and spermatogenesis in men with IHH, however a small subset of IHH men, fail to reach a normal testicular volume and produce sperm on this therapy [94] . Pitteloud in studying 76 IHH men undergoing
GnRH therapy for 12 -24 months to define predictors of outcome of longterm GnRH therapy concluded anosmia was not an independent predictor, however favourable predictors of achieving an adult testicular size and consequently optimizing spermatogenesis are prior history of sexual maturation, with a baseline inhibin (IB) > 60 pg/ml along with absence of cryptorchidism [101] . 
Role of rFSH Priming Followed by GnRH Therapy
Dwyer et al. 2013 conducted a randomized open label prospective trial to see if there is any benefit of giving recombinant FSH (rFSH) pretreatment for 4 months followed by pulsatile GnRH therapy vs GnRH therapy alone in a group of CHH patients with prepubertal testis (<4 ml), no cryptorchidsm, and no prior gonadotropin therapy and found rFSH increased inhibin B levels into normal range and doubled testicular vo-lume. Histological analysis showed proliferation of sertoli cells (SC) and spermatogonia, a decreased SC to germ cell ratio from 0.74 to 0.35 and SC cytoskeletal rearrangements. Although with pulsatile GnRH similar hormones and significant testicular growth was exhibited, all men receiving rFSH developed sperm in their ejaculate (7/7 vs 4/6 in GnRH only group) and showed trends towards higher maximal sperm counts and hence concluded that rFSH not only appears to maximize the SC population, but also induces morphologic changes, suggesting broader developmental roles [104] . This maybe in accordance with the study of Pitteloud et al. who found after studying 25 patients of IHH that. GnRH deficient men undergoing GnRH induced sexual maturation displayed an inverse responsiveness to GnRH and baseline testicular size and I(B) levels. This observation implied that increasing seminiferous tubule maturity represents the major constraint on FSH responsiveness to GnRH in early puberty. In contrast LH responsiveness to GnRH corelated directly with duration of GnRH exposure [105] .
However in view of small numbers Dwyer et al. proposed that although data appears promising a multicenter trial is recommended to optimize the optimal strategy for treating the very severe CHH cases.
Insulin like Peptide 3 (INSL3)
A testicular hormone secreted during fetal life, neonatal period and after puberty was 
IHH in Women
Shaw et al. retrospectively studied 248 female patients of IHH from 1980 to 2010 seen in Massachussets general hospital. The clinical presentation varied from primary amenorrhea and absence of any sexual characteristics to spontaneous breast development and occasional menses. In this cohort rare sequence variants were present in all known genes associated with GnRH deficiency, including novel identification of GnRH deficient women with KAL 1 variants. They concluded that the pathogenic mechanism through which KAL 1 variant disrupts female reproductive development requires further investigation [108] . IHH in women (as in men) is treated with sex hormones. Initially low dose estradiol (1 mg) is begun in order to develop sexual characteristics and then it is gradually increased in doses [109] - [112] . From the second year of treatment estrogen supplementation with chlormadinone acetate is done [110] - [112] . Desire for pregnancy warrants pulsatile GnRH therapy to stimulate production of serum FSH and LH [2] [113] . Further the importance of GnRH administration should be intermittent and pulsatile to be able to restore activity of the reproductive axis in patients with HA and other disorders of GnRH deficiency was emphasized by Knobil et al. [114] . Tonic exposure of GnRH inhibited pituitary gonadotropin scecretion paradoxically [115] . Although chances of success is good, where GnRH is not available, LH or FSH can be administered alternatively [116] .
Just like in male subjects Abel et al. repeated the study in 37 IHH women treated with i/v pulsatile GnRH therapy (75 ng/kg/bolus) (retrospective study , all patients over 16yrs with 46%anosmic and tested for all 14 genes and found that during first cycle 60% (22/37) recreated normal cycles, 30% (12/37) demonstrated altered gonadotropin response indicating pituitary resistance and 10% (3/37) an exaggerated FSH response consistent with ovarian resistance. Mutations in CHD7, FGFR1, KAl1, TAC3, TACR3 were documented in IHH women with normal cycles, whereas mutations were identified in GNRHR, PROKR2 and FGFR1 in those with pituitary resistance. Women with ovarian resistance were mutation negative. Thus they concluded that although physiological replacement with GnRH recreates normal menstrual dynamics in most IHH ladies [117] , Hypogonadotropic responses in first week of treatment identify a subset of women with pituitary dysfunction, only some of whom have GNRHR mutations.IHH women with hypergonadotropic responses to GnRH replacement, consistent with an additional ovarian defect did not have mutations in genes known to cause IHH similar to their findings in men with evidence of an additional testicular defect. Hence they hypothesized that identification of women with abnormal responses to physiological GnRH replacement would give greater insight into the pathogenesis of HH. Hyper/hypogonadotropic responses would implicate an ovarian/pituitary defect, respectively. Such findings would suggest that genes involved in gonadotropin or ovarian development and function that are also expressed in the hypothalamus should be given greater consideration in the search for new IHH genes.
Still controversy exists on the sexuality and intimate relations of men with severe CHH accompanied by cryptorchidism and micropenis [118] . Since there is a negative prognostic value of cryptorchidism and low testicular volume for the future fertility of patients with severe CHH, a trial of earlier gonadotropin therapy during the neonatal or normal pubertal period is warranted and just may prove beneficial, both in terms of testicular hypertrophy and in terms of future fertility [119] - [121] .
Role of Estradiol (in Male CHH)
Trabados et al. studying 91 men of IHH, syndrome found male hypogonadism in CHH is associated with profound E2 insufficiency which can be overcome by aromatizable androgen (Tenanthate) or combined gonadotropin (FSH-HCG) therapy, but not dihydrotestosterone (DHT) contrary to Klinefelters syndrome [122] . This E2 deficiency is also associated with abnormal bone development, noteenage growth spurt and osteopenia or osteoporosis [123] - [125] , reviewed in [126] . Further Rochira et al. reported 4 cases of tall stature without Growth hormone deficiency who had a impaired response of GH to GHRH-ARG as compared to normal subjects and who had significantly lower IGF1 levels as compared to normal subjects and both IGF1 peak and concentrations were not modified by estrogen therapy in men with aromatase deficiency and concluded insulin as the cause of tall stature rather than GH for the marked increase in height due to nonclosure of epiphyses [127] . Besides that for normal physiology, Pitteloud et al. 2008 showed that for Inhibition of LH secretion by T in men aromatization is required for its pituitary effect but not its hypothalamic effect [128] .
Further since Kp 10 is a potent stimulator of LH and increases pulse frequency in men and thereby LH and testosterone levels in normal men there may be a potential role of Kp agonists in HH due to KISS 1/KISS1R mutations ( [129] , reviewed in [130] ).
Although TAC3/TAC3R mutations also are associated with IHH, administration of NKB was not accompanied by increase in serum LH and testosterone levels, hence role of NKB doesn't appear to be useful in treating these patients presenting with TAC3/ TACR3 mutations [131] however since KISS1 appears to be downstream of NKB signaling, pulsatile gonadotropin secretion is restored by kisspeptin administration to patients with HH secondary to NKB and or its receptor [132] [133].
Conclusions
The very concept of classifying IHH into anosmic/hyposmic KS and normosmic IHH gets challenged by the study of Lewkowitz Shpunoff although till now we have been tuned to working on the basis of KS/nIHH. This was further substantiated by the study by Valetti et al. where olfactory bulb was absent in patients with anosmic/hyposmic IHH, and otherwise there was no difference in the developmental anomalies in the 2 groups. Although this study was a not well conducted in terms of numbers, smell test and neither fully prospective but it does add to the results of Lewkowitch et al. in that there is no point in classifying as two separate disorders but both are part of same spectrum. Despite identification of so many genes like 9 of those which were earlier consi-dered as for the KS group as they affect the migration or GnRH development eg KAL1, FGF8. FGFR1, HS-6TS1, CHD7, WDR11, PROK2/PROKR2/SEMA3A these account for not more than 30% -32% cases of KS. Addition of "FGF Synexpression group" adds to the list besides the genes considered so far associated with GnRH function/secretion. Still a lot of controversial issues remain regarding role of PROK signaling as highlighted in ref. [27] regarding absence of PROK receptors on GnRH neurons, mode of inheritance-digenic/oligogenic [43] with presence of PROK2 mutations even in normosmic HH and thus extending the role beyond olfactory bulb development and GnRH neuronal migratrion and absence of any defect in homozygous mutations while most of human presentations being in heterozygous mutations. Although some answers are provided by the link between TSHZ1, which bound to and regulated the expression of gene encoding PROKR2, a GPCR essential for OB development. Further recently that there maybe an ethnic role is highlighted by greater presence of PROKR2 mutations in KS patients from Maghreb as compared to European origin patients (23.3% vs 5.1%) [30] . Further more work needs to be done on other transcription factors as has been shown for SOX10 i.e., loss of function mutations in SOX 10 is associated with KS along with deafnessal though not in KS without deafness and highlighting importance of neural crest as well as part origin for GnRH neurons [134] . Similar work needs to be done for other transcription factors in view of genetic overlap of other midline forebrain disorders like SOD and HPE with KS. Further genes involved in development of hypothalamus, pituitary and gonads in both males as well as females who fail to respond to pulsatile GnRH therapy should be targeted for understanding reason for 4 -5 times greater preponderance in males-whether it is explained just by X linked transmission or we are missing some female cases due to underreporting in mild hypogonadism or primary amenorrhea not brought forward [135] . The role of SDF-GABA signaling in promoting linear axophilic migration of GnRH neurons through interaction of its receptors, chemokinereceptor 4 and 7 (CXCR4/CXCR7), needs further investigation like other molecules, hepatocyte growth factor (HGF), deleted in colorectal cancer (DCC), Slit2 and Robo3 as suggested by Wray et al. and Cariboni respectively in animal models [136] - [139] .
